/ /

  • linkedin
  • Increase Font
  • Sharebar

    Integrin peptide yields positive outcomes for VMA, VMT in phase II trial

    Dual mechanisms of action appear to inhibit new blood vessel formation, reduce leakage


    The “ideal” patient for ALG-1001 is someone with symptomatic VMA or VMT who is contemplating vitrectomy but does not want to undergo a difficult surgical procedure, Dr. Tolentino said. There are no contraindications right now for its use.

    Although Allegro Ophthalmics had positive results from the phase II Luminate trial for VMA or VMT, the company noted it is currently focused on trials with the drug for other ocular conditions to further investigate the drug’s dual mechanisms of action (anti-angiogenesis and vitreolysis). This includes phase II study in patients with vision loss secondary to centrally involved diabetic macular edema and posterior vitreous induction in patients with nonproliferative diabetic retinopathy.

    The company also noted it will begin a phase II study to test ALG-1001 to treat wet age-related macular degeneration, refractory diabetic macular edema, and adjunctive to pars plana vitrectomy.

    “Allegro will make further determinations on the next steps for its VMT program after the full analysis of the data and meeting with the FDA,” Dr. Tolentino said.


    Michael Tolentino, MD

    E: [email protected]

    Dr. Tolentino is a clinical investigator for the phase II VMT study.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results